Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer Clinical Trial

Official title:

Sunitinib Either Before or After Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00626509
• Other study ID #: GICR-GIR-1
• Secondary ID: CDR0000588423EUD
• Status: Recruiting
• Phase: Phase 2
• First received: February 28, 2008
• Last updated: August 9, 2013
• Start date: February 2008

Study information

• Verified date: June 2009
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: Unspecified
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery. It is not yet known whether sunitinib is more effective when given before or after surgery in treating kidney cancer.

PURPOSE: This randomized phase II trial is studying the side effects of sunitinib and to compare how well it works when given before or after surgery in treating patients with metastatic kidney cancer.

Description:

OBJECTIVES:

Primary

• To compare the activity of sunitinib malate when administered before vs after cytoreductive nephrectomy, in terms of response rate, in patients with metastatic renal cell carcinoma.

• To compare the safety of these regimens in these patients.

Secondary

• To compare the time to progression in patients treated with these regimens.

• To compare the duration of response in patients treated with these regimens.

• To compare the overall survival of patients treated with these regimens.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients undergo cytoreductive nephrectomy. Patients then receive adjuvant therapy comprising oral sunitinib malate once daily for 4 weeks. Treatment repeats every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment beyond 1 year at the discretion of the investigator.

• Arm II: Patients receive neoadjuvant therapy comprising oral sunitinib malate once daily for 4 weeks. Treatment repeats every 6 weeks for 2 courses. After completion of neoadjuvant therapy, patients undergo cytoreductive nephrectomy followed by adjuvant sunitinib malate as in arm I.

After completion of study therapy, patients are followed every 2 months for up to 1 year.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 110
• Est. primary completion date: January 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Proven metastatic renal cell carcinoma

• Measurable disease (according to RECIST criteria)

• Eligible for cytoreductive nephrectomy

• Primary tumor is considered amenable to surgical extirpation by the attending surgeon

• Thrombosis of the inferior vena cava below the epathic veins allowed

• No symptomatic brain metastases

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1

• Adequate hematology and coagulation

• Amylase and lipase normal

• Adequate hepatic, renal, and cardiac function

• Not pregnant

• Negative pregnancy test

• No uncontrolled hypertension and/or clinically significant cardiovascular events or disease within the past 12 months

• No other cancer within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

• No prior early nephrectomy due to clinical condition

• No prior systemic therapy for renal cell carcinoma (e.g., chemotherapy, hormonal therapy, interferon, interleukin-2, lymphocyte-activated killer cells, or other biological response modifiers)

• More than 12 days since prior potent CYP3A4 inducers, including any of the following:

• Rifampin

• Rifabutin

• Carbamazepine

• Phenobarbital

• Phenytoin

• St. John's wort

• Efavirenz

• Tipranavir

• More than 7 days since prior potent CYP3A4 inhibitors, including any of the following:

• Ketoconazole

• Itraconazole

• Clarithromycin

• Erythromycin

• Diltiazem

• Verapamil

• Delavirdine

• Indinavir

• Saquinavir

• Ritonavir

• Atazanavir

• Nelfinavir

• No other concurrent approved or investigational anticancer treatment, including chemotherapy, biological response modifiers, hormonal therapy, or immunotherapy

• No concurrent participation in any other treatment clinical trial

• No concurrent palliative radiotherapy or surgery

• No concurrent drugs with proarrhythmic potential, including any of the following:

• Terfenadine

• Quinidine

• Procainamide

• Disopyramide

• Sotalol

• Probucol

• Bepridil

• Haloperidol

• Risperidone

• Indapamide

• Flecainide

• Concurrent bisphosphonate therapy for metastatic bone disease allowed provided therapy was initiated at least 4 weeks prior to the first dose of study drug

Study Design

Allocation: Randomized, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Kidney Cancer
• Kidney Neoplasms

Intervention

Drug:
• sunitinib malate

Procedure:
• adjuvant therapy

• neoadjuvant therapy

• therapeutic conventional surgery

Locations

Country	Name	City	State
Italy	Ospedale Sacro Cuore	Negrar

Sponsors (1)

Lead Sponsor	Collaborator
Gruppo Italiano Carcinoma Renale

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall objective tumor response rate (complete response, partial response, stable disease, and progressive disease) as assessed by RECIST criteria			No
Primary	Adverse events as assessed by NCI CTCAE v3.0			Yes
Secondary	Time to progression			No
Secondary	Duration of response			No
Secondary	Overall survival			No